<DOC>
	<DOCNO>NCT02105701</DOCNO>
	<brief_summary>This efficacy safety study grazoprevir ( MK-5172 ) combination elbasvir ( MK-8742 ) without ribavirin ( RBV ) participants chronic hepatitis C virus ( HCV ) genotype ( GT ) 1 , 4 , 6 infection fail prior therapy pegylated interferon RBV . The primary study hypothesis least one study arm , percentage participant achieve sustained viral response 12 week end study treatment ( SVR12 ) superior 58 % .</brief_summary>
	<brief_title>Study Efficacy Safety Grazoprevir ( MK-5172 ) + Elbasvir ( MK-8742 ) With Without Ribavirin Participants With Hepatitis C Genotype 1 , 4 , 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin ( MK-5172-068 )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Documented chronic HCV GT1 , GT4 , GT6 evidence nontypable mixed genotype infection ( positive antiHCV antibody , HCV ribonucleic acid [ RNA ] , list GTs least 6 month prior screen must confirm screen lab result ) Cirrhosis define liver biopsy show METAVIR F4 ; Fibroscan show result &gt; 12.5 kilopascals ( kPa ) ; FibroSure® ( Fibrotest® ) score &gt; 0.75 aspartate aminotransferase ( AST ) : platelet ratio index ( APRI ) &gt; 2 Absence cirrhosis define liver biopsy show absence cirrhosis ; Fibroscan result ≤ 12.5 kPa ; Fibrosure® ( Fibrotest® ) score ≤ 0.48 APRI ≤ 1 Previous HCV treatment status peginterferon/RBV Null responder ; peginterferon/RBV Partial responder ; peginterferon/RBV Treatment Relapse For human immunodeficiency virus ( HIV ) coinfected participant : document HIV1 infection ; currently naïve treatment antiretroviral therapy ( ART ) plan initiate ART treatment participate study ; HIV ART least 8 week prior study entry ( dual nucleoside reverse transcriptase inhibitor [ NRTI ] backbone tenofovir abacavir either emtricitabine lamivudine plus raltegravir ( dolutegravir rilpivirine ) ( change HIV regimen allow within 4 week randomization ) ; cluster differentiation 4 ( CD4 ) + Tcell count &gt; 200 cells/mm^3 screening ; document undetectable plasma HIV1 RNA least 8 week prior screen ; participant ART , HIV RNA must &lt; 50,000 copies/mL ; must least one viable antiretroviral regimen alternative beyond current regimen event HIV virologic failure development antiretroviral drug resistance Agree use two acceptable method birth control least 2 week prior Day 1 continue least 6 month last dose study drug , longer dictate local regulation ; male participant ( whose partner ) reproductive potential eligible without require use contraception Evidence decompensated liver disease manifest presence history ascites , esophageal gastric variceal bleeding , hepatic encephalopathy sign symptom advance liver disease For participant cirrhosis , participant ChildPugh Class B C PughTurcotte ( CPT ) score &gt; 6 , must exclude Coinfected hepatitis B virus Has previous directacting antiviral treatment History malignancy &lt; =5 year prior except adequately treat basal cell squamous cell skin cancer situ cervical cancer carcinoma situ ; evaluation active suspect malignancy Has cirrhosis liver image show evidence hepatocellular carcinoma ( HCC ) evaluation HCC Taking plan take HIV therapy include ritonavirboosted unboosted protease inhibitor , efavirenz etravirine Currently participate participate study investigational compound within 30 day sign informed consent willing refrain participate another study course study Clinicallyrelevant drug alcohol abuse within 12 month Pregnant , breastfeeding , expect conceive donate egg sperm Day 1 continue least 6 month last dose study drug , longer dictate local regulation ; male whose female partner ( ) is/are pregnant History organ transplant ( include hematopoietic stem cell transplant ) cornea hair Poor venous access History gastric surgery ( e.g. , staple , bypass ) history malabsorption disorder ( e.g. , celiac sprue disease ) Hemoglobinopathy , include , limited , thalassemia major Any medical condition requiring , likely require , chronic systemic corticosteroid , tumor necrosis factor ( TNF ) antagonists , immunosuppressant drug course trial For participant HIV , history opportunistic infection precede 6 month For participant HIV , use HIV drug dual NRTI backbone tenofovir abacavir either emtricitabine lamivudine plus raltegravir ( dolutegravir rilpivirine ) Evidence history chronic hepatitis cause HCV , include limited nonalcoholic steatohepatitis ( NASH ) , druginduced hepatitis , autoimmune hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>